Lv1
60 积分 2024-06-12 加入
Immunogenicity risk assessment and mitigation for engineered antibody and protein therapeutics
1个月前
已完结
Improvement of clinical parameters in HDV patients with advanced compensated cirrhosis treated with Bulevirtide monotherapy for 48 weeks
3个月前
已完结
Safety and efficacy of REP 2139 and pegylated interferon alfa-2a for treatment-naive patients with chronic hepatitis B virus and hepatitis D virus co-infection (REP 301 and REP 301-LTF): a non-randomised, open-label, phase 2 trial
3个月前
已完结
Peginterferon alfa-2a plus tenofovir disoproxil fumarate for hepatitis D (HIDIT-II): a randomised, placebo controlled, phase 2 trial
3个月前
已完结
A phase 2 dose-escalation study of lonafarnib plus ritonavir in patients with chronic hepatitis D: final results from the Lonafarnib with ritonavir in HDV-4 (LOWR HDV-4) study
3个月前
已完结
A phase 2 study exploring once daily dosing of ritonavir boosted lonafarnib for the treatment of chronic delta hepatitis – end of study results from the LOWR HDV-3 study
3个月前
已完结
Treating chronic hepatitis delta: The need for surrogate markers of treatment efficacy
3个月前
已完结
Baseline bile acid levels but not bile acid increases during bulevirtide treatment of hepatitis D are associated with HDV RNA decline
3个月前
已完结
Safety and efficacy of bulevirtide in combination with tenofovir disoproxil fumarate in patients with hepatitis B virus and hepatitis D virus coinfection (MYR202): a multicentre, randomised, parallel-group, open-label, phase 2 trial
3个月前
已完结
OS-122 Bulevirtide in combination with pegylated interferon alfa-2a shows a sustained off-treatment response in the liver
4个月前
已完结
皖公网安备34019202002308
